PT - JOURNAL ARTICLE AU - Kimberly A. Kraynyak AU - Elliott Blackwood AU - Joseph Agnes AU - Pablo Tebas AU - Mary Giffear AU - Dinah Amante AU - Emma L. Reuschel AU - Mansi Purwar AU - Aaron Christensen-Quick AU - Neiman Liu AU - Viviane Andrade AU - Malissa C. Diehl AU - Snehal Wani AU - Martyna Lupicka AU - Albert Sylvester AU - Matthew P. Morrow AU - Patrick Pezzoli AU - Trevor McMullan AU - Abhijeet J. Kulkarni AU - Faraz I. Zaidi AU - Drew Frase AU - Kevin Liaw AU - Trevor R.F. Smith AU - Stephanie J. Ramos AU - John Ervin AU - Mark Adams AU - Jessica Lee AU - Michael Dallas AU - Ami Shah Brown AU - Jacqueline E. Shea AU - J. Joseph Kim AU - David B. Weiner AU - Kate E. Broderick AU - Laurent M. Humeau AU - Jean D. Boyer AU - Mammen P. Mammen, Jr. TI - SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial AID - 10.1101/2021.10.06.21264584 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.06.21264584 4099 - http://medrxiv.org/content/early/2021/10/10/2021.10.06.21264584.short 4100 - http://medrxiv.org/content/early/2021/10/10/2021.10.06.21264584.full AB - Background Additional SARS-CoV-2 vaccines that are safe and effective as both primary series and booster remain urgently needed to combat the COVID-19 pandemic. Here we describe the safety and durability of the immune response from two doses of a DNA vaccine (INO-4800) targeting the full-length Spike antigen and a subsequent homologous booster dose.Methods INO-4800 was evaluated in 120 healthy participants across three dose groups (0.5 mg, 1.0 mg and 2.0 mg), each stratified by age. INO-4800 was injected intradermally followed by electroporation at 0 and 4 weeks followed by an optional booster dose 6-10.5 months following the second dose.Results INO-4800 was well-tolerated, with no treatment-related serious adverse events reported. Most adverse events were mild in severity and did not increase in frequency with age and subsequent dosing. A durable antibody response was observed 6 months following the second dose; a homologous booster dose significantly increased immune responses. Cytokine producing T cells and activated CD8+T cells with lytic potential were detected in the 2.0 mg dose group.Conclusion INO-4800 was well-tolerated as a 2-dose series and as a homologous booster dose in all adults, including the elderly. These results support further development of INO-4800 as a primary series and as a booster.Competing Interest StatementKAK, EB, JA, MG, DA, ACQ, NL, VA, MD, SW, ML, AS, MPM, PP, TM, TRFS, SJR, JL, MD, ASB, JES, JJK, KEB, LMH, JDB, MPM, Jr. report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial; other from Inovio Pharmaceuticals including salary and stock options, outside the submitted work. PT, ELR, MP, AJK, FIZ, DF, KL, JE, MA, and DBW report grants from Coalition for Epidemic Preparedness Innovations, during the conduct of the trial. D.B.W. participates in industry collaborations and has received renumeration for individual services. In the interest of disclosure, D.B.W. reports the following paid associations with commercial partners: Pfizer (Advisory Board), Geneos (Advisory, SRA), Advaccine (Advisory) Astrazeneca (Advisory, Speaker), Inovio (BOD, SRA, Stock ownership), Sanofi (Advisory Board), BBI (Advisory Board, SRA). All other authors declare no potential conflicts of interest.Clinical TrialNCT04336410Funding StatementThis work is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and Inovio Pharmaceuticals, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the institutional review board of each clinical site (The University of Pennsylvania Clinical Trials Unit in Philadelphia, PA; the Alliance for Multispecialty Research in Kansas City, MO; and the Alliance for Multispecialty Research in Lexington, KY.) and all participants provided written informed consent prior to enrollment. The trial was conducted under current Good Clinical Practices (GCP).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe preliminary COVID19-001 Phase 1 clinical study datasets are subject to access restriction to protect subject confidentiality as the clinical study is still ongoing.